Saliva substitute mouthwash in nasopharyngeal cancer survivors with xerostomia: a randomized controlled trial
ConclusionIASS mouthwash significantly reduces subjective xerostomia scores measured using SXI and improves objective measurement of salivary flow using UWS among nasopharyngeal cancer survivors with xerostomia.Clinical relevanceIASS is significantly more effective in improving subjective and objective xerostomia measurements compared to non-immunologically active mouthwash. Additionally, this treatment is very safe, with superior side effect profiles.Trial registrationClinicalTrials.gov Identifier: NCT04491435
Source: Clinical Oral Investigations - Category: Dentistry Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Clinical Trials | Dentistry | Nasopharyngeal Cancer | Oral Cancer | Study | Xerostomia